Xylem Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 13, 2026, disclosing the appointment of D. Christian Koch as a new member of its Board of Directors, effective immediately.
BlackSky Technology Inc. filed a Form 8-K on August 13, 2026, disclosing that the New York Stock Exchange notified the company on August 7, 2026, of its determination to commence delisting proceedings against the company's warrants and immediately suspend their trading.
Tyson Foods, Inc. filed a Form 8-K with the SEC on August 13, 2026, disclosing plans to end operations at two beef processing facilities and pursue the sale of a third.
Profound Medical Corp. filed a Form 8-K on August 13, 2026, under Item 7.01 (Regulation FD Disclosure), announcing the launch of a patient advocacy initiative called Let's Huddle via a press release issued the same day.
Marqeta, Inc. filed a Form 8-K on August 13, 2026, disclosing that Chief Accounting Officer and Senior Vice President of Finance Sarah Barkema informed the company of her resignation effective August 21, 2026.
TWFG, Inc. filed a Form 8-K on August 13, 2026, disclosing that it entered into an Amended and Restated Credit Agreement on August 12, 2026, providing for a $125,000,000 revolving credit facility with PNC Bank, National Association as administrative agent.
Newmont Corporation filed a Form 8-K on August 13, 2026, disclosing that on August 10, 2026, it entered into a Second Amended and Restated Limited Liability Company Agreement for Nevada Gold Mines LLC with Barrick Mining Corporation, governing the contribution of three mining projects …
The Bank of New York Mellon Corporation filed a current report on August 13, 2026, disclosing that its Board of Directors elected Vikram Malhotra as an independent director, effective October 1, 2026.
A Form 4 filed on August 13, 2026 with the U.S. Securities and Exchange Commission disclosed that James W. Keyes, a director of Murphy USA Inc. (NYSE:MUSA), disposed of 2,000 shares of common stock on August 11, 2026 through a gift transaction.
AbCellera Biologics Inc. filed a Form 8-K on August 13, 2026, disclosing that it entered into an underwriting agreement on August 12, 2026, for an underwritten public offering of common shares and pre-funded warrants expected to raise approximately $187.0 million in net proceeds.